Drug Profile

Research programme: OX40 receptor agonists - AstraZeneca/AgonOx/Providence cancer center

Alternative Names: OX-40 program; OX-40L; OX40L-FP

Latest Information Update: 29 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AgonOx; Providence Cancer Center
Developer AstraZeneca
Class Immunoglobulins; Proteins
Mechanism of Action OX40 ligand modulators; OX40 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer

Most Recent Events

28 May 2019 No recent reports of development identified for preclinical development in Cancer in USA
01 Apr 2017 Preclinical development in Cancer is ongoing in USA
01 Apr 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association of Cancer Research (AACR-2017)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com